Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 4Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

Rituximab 44Cyclophosphamide 38Prednisone 26Doxorubicin 25Vincristine 20Magnetic Resonance Spectroscopy 20Lenalidomide 19Specimen Handling 18Gemcitabine 18Biopsy 15polatuzumab vedotin 14Oxaliplatin 14glofitamab 12obinutuzumab 11ibrutinib 10Etoposide 10CT-P10 9fludarabine 8Dexamethasone 8prednylidene 7pembrolizumab 7deltacortene 7Prednisolone 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6acalabrutinib 6fludarabine phosphate 5R-CHOP protocol 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × decitabine and cedazuridine drug combination × 90 days × Clear all
NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡